Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

Martin Bögemann; Neal D. Shore; Matthew R. Smith; Teuvo L.J. Tammela; Albertas Ulys; Egils Vjaters; Sergey Polyakov; Mindaugas Jievaltas; Murilo Luz; Boris Alekseev; Thierry Lebret; Martin Schostak; Frank Verholen; Marie Aude Le Berre; Shankar Srinivasan; Jorge Ortiz; Ateesha F. Mohamed; Toni Sarapohja; Karim Fizazi

doi:10.1016/j.eururo.2022.11.018

Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

Martin Bögemann, Neal D. Shore, Matthew R. Smith, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Thierry Lebret, Martin Schostak, Frank Verholen, Marie Aude Le Berre, Shankar Srinivasan, Jorge Ortiz, Ateesha F. Mohamed, Toni Sarapohja, Karim Fizazi

Résultats de recherche: Contribution à un journal › !!Comment/debate

1 Citation (Scopus)

Résumé

The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

langue originale	Anglais
Pages (de - à)	e60
journal	European Urology
Volume	83
Numéro de publication	2
Les DOIs	https://doi.org/10.1016/j.eururo.2022.11.018
état	Publié - 1 févr. 2023

Accès au document

10.1016/j.eururo.2022.11.018

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Bögemann, M., Shore, N. D., Smith, M. R., Tammela, T. L. J., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Lebret, T., Schostak, M., Verholen, F., Le Berre, M. A., Srinivasan, S., Ortiz, J., Mohamed, A. F., Sarapohja, T., & Fizazi, K. (2023). Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). European Urology, 83(2), e60. https://doi.org/10.1016/j.eururo.2022.11.018

Bögemann, Martin ; Shore, Neal D. ; Smith, Matthew R. et al. / Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time : Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). Dans: European Urology. 2023 ; Vol 83, Numéro 2. p. e60.

@article{d7bf258cf34e4a5b8d22cd10fffde2ef,

title = "Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))",

abstract = "The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.",

author = "Martin B{\"o}gemann and Shore, {Neal D.} and Smith, {Matthew R.} and Tammela, {Teuvo L.J.} and Albertas Ulys and Egils Vjaters and Sergey Polyakov and Mindaugas Jievaltas and Murilo Luz and Boris Alekseev and Thierry Lebret and Martin Schostak and Frank Verholen and {Le Berre}, {Marie Aude} and Shankar Srinivasan and Jorge Ortiz and Mohamed, {Ateesha F.} and Toni Sarapohja and Karim Fizazi",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2023",

month = feb,

day = "1",

doi = "10.1016/j.eururo.2022.11.018",

language = "English",

volume = "83",

pages = "e60",

journal = "European Urology",

issn = "0302-2838",

number = "2",

}

Bögemann, M, Shore, ND, Smith, MR, Tammela, TLJ, Ulys, A, Vjaters, E, Polyakov, S, Jievaltas, M, Luz, M, Alekseev, B, Lebret, T, Schostak, M, Verholen, F, Le Berre, MA, Srinivasan, S, Ortiz, J, Mohamed, AF, Sarapohja, T & Fizazi, K 2023, 'Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))', European Urology, VOL. 83, Numéro 2, p. e60. https://doi.org/10.1016/j.eururo.2022.11.018

Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). / Bögemann, Martin; Shore, Neal D.; Smith, Matthew R. et al.
Dans: European Urology, Vol 83, Numéro 2, 01.02.2023, p. e60.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time

T2 - Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018))

AU - Bögemann, Martin

AU - Shore, Neal D.

AU - Smith, Matthew R.

AU - Tammela, Teuvo L.J.

AU - Ulys, Albertas

AU - Vjaters, Egils

AU - Polyakov, Sergey

AU - Jievaltas, Mindaugas

AU - Luz, Murilo

AU - Alekseev, Boris

AU - Lebret, Thierry

AU - Schostak, Martin

AU - Verholen, Frank

AU - Le Berre, Marie Aude

AU - Srinivasan, Shankar

AU - Ortiz, Jorge

AU - Mohamed, Ateesha F.

AU - Sarapohja, Toni

AU - Fizazi, Karim

PY - 2023/2/1

Y1 - 2023/2/1

N2 - The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

AB - The publisher regrets that during the typesetting of this paper, some less-than-or-equal-to signs were inadvertently reversed. This has now been corrected and will subsequently appear correctly in print. The publisher would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85145287074&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2022.11.018

DO - 10.1016/j.eururo.2022.11.018

M3 - Comment/debate

C2 - 36526492

AN - SCOPUS:85145287074

SN - 0302-2838

VL - 83

SP - e60

JO - European Urology

JF - European Urology

IS - 2

ER -

Bögemann M, Shore ND, Smith MR, Tammela TLJ, Ulys A, Vjaters E et al. Erratum to “Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial” [Eur Urol 2022] (European Urology, (S0302283822025325), (10.1016/j.eururo.2022.07.018)). European Urology. 2023 févr. 1;83(2):e60. doi: 10.1016/j.eururo.2022.11.018